In this session at AACR 2024, BLOODPAC panelists will discuss the ways we are currently conceptualizing cancer risk in the setting of current cancer screening guidelines and how a shift in thinking and terminology may be warranted with the introduction of new single and multi-cancer early detection technologies. Panelists include:

• Elizabeth (Betsy) O’Donnell, MD, DipABLM (Director of Early Detection and Prevention of Malignant Conditions, Dana-Farber Cancer Institute)

• Bree Mitchell, PhD (Senior Director, Translational Medicine and Research, Natera)

• Jeff Allen, PhD (President and CEO, Friends of Cancer Research)

• Lauren Leiman, MBA (Executive Director, BLOODPAC)

• Christina Clarke Dur, PhD MPH (VP Epidemiology, Distinguished Scientist, GRAIL)

• Victoria Raymond, MS (Sr. Director, Medical Affairs, Guardant Health)

• Wendy Rubinstein, PhD (Senior Scientific Officer, Division of Cancer Prevention, National Cancer Institute)